Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §2

KPV — pharmacology

Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.

Document identifier
CEI-MN-034/2
Series
Compound monograph
Version
1.3
Published
01 Feb 2023
Last reviewed
01 Mar 2024
Next review
01 Mar 2026
Identifier
10.71829/cei.mono.34
Certainty
Very low
Cycle
2023 Q1

§2Pharmacology

§2.1Molecular targets

Table 2. Molecular targets recorded for KPV, with the character of the interaction and the potency where the Institute holds it.

TargetInteractionNote
Mechanism partially characterisedMelanocortin-receptor-independentAnti-inflammatory activity persists in melanocortin receptor knockout models, indicating a distinct pathway; NF-κB inhibition and PepT1-mediated epithelial uptake have been reported

§2.2Mechanism of action

KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine production in epithelial and immune cells. Reported uptake through the intestinal peptide transporter PepT1 provides a plausible route for local action in intestinal epithelium after oral administration, which is the most mechanistically coherent application described for it.[1,2]

§2.3Pharmacokinetics

No human pharmacokinetic characterisation of KPV has been identified. In the absence of a half-life, a volume of distribution and a clearance estimate, no dosing interval used in practice can be related to any exposure that produced an effect in any study, and the Institute records this as a first-order gap rather than a detail.

§2.4Interactions

  • Not characterised

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
  2. Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.